Related Experiment Video
Updated: Feb 19, 2026
12:04
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
29.6K
Update on large cell neuroendocrine carcinoma.
Kenzo Hiroshima1, Mari Mino-Kenudson2
1Department of Pathology, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.
Translational Lung Cancer Research
|November 9, 2017
Summary
Large cell neuroendocrine carcinoma (LCNEC) is a heterogeneous lung cancer. Molecular profiling reveals SCLC-like and NSCLC-like subsets, impacting morphology and treatment strategies for better patient outcomes.
Area of Science:
- Pulmonology
- Oncology
- Pathology
Background:
- High-grade neuroendocrine lung carcinomas include large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC).
- Distinguishing LCNEC from SCLC can be challenging due to overlapping features and borderline cases.
- LCNEC is increasingly recognized as a heterogeneous tumor group with distinct biological subsets.
Purpose of the Study:
- To investigate the molecular and morphological heterogeneity of LCNEC.
- To identify distinct biological subsets within LCNEC.
- To explore the implications of LCNEC heterogeneity on treatment strategies.
Main Methods:
- Molecular profiling using next-generation sequencing (NGS).
- Morphological assessment of tumor subtypes.
- Review of treatment outcomes for early and advanced stage LCNEC.
Main Results:
- NGS identified two main LCNEC subsets: SCLC-like (TP53/RB1 mutations) and NSCLC-like (NSCLC-associated alterations).
- SCLC-like LCNEC shows SCLC morphology, while NSCLC-like LCNEC exhibits NSCLC morphology, with some overlap.
- Adjuvant platinum/etoposide chemotherapy may improve outcomes for resected LCNEC; treatment response in advanced disease remains debated.
Conclusions:
- LCNEC is biologically and morphologically heterogeneous, with SCLC-like and NSCLC-like subsets.
- Understanding these subsets is crucial for accurate diagnosis and tailored treatment approaches.
- Further research into LCNEC biology will drive novel therapeutic strategies for improved patient management.
